Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
Shares of Vertex Pharmaceuticals Inc. VRTX slid 0.46% to $408.76 Friday, on what proved to be an all-around rough trading ...
Yahoo2d
Dick Parsons, Emergency Fixer for Troubled Companies, Dies at 76
With his preternatural calm, charm and instincts for corporate politics, Parsons ascended rapidly through the ranks of ...
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
This was the stock's fourth consecutive day of gains.
Gene Therapy Market Analysis,Growth, Insights And Future Outlook | Exactitude Consultancy
Technological Advancements : Ongoing innovations in gene delivery methods, such as the development of next-generation viral and non-viral vectors, are expected to drive substantial growth in the gene ...
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...
Shareholder Rights Advocates at Levi & Korsinsky Investigate Vertex Pharmaceuticals Incorporated (VRTX) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Jim Cramer on Vertex Pharmaceuticals Incporated (VRTX): ‘This Is Hardly Down For The Year. I Think It Can Still Go Lower’
We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going ...
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and ...
MM&M8d
Rx Rundown: Sanofi, Novartis, Roche and more
The Advanced Research Projects Agency for Health (ARPA-H) awarded TigaTx up to $33.5 million in funding. Tessera Therapeutics ...
Vertex’s non-opioid drug succeeds in back pain trial
Vertex Pharmaceuticals' suzetrigine shows promising results in treating painful lumbosacral radiculopathy, but stock falls ...
Business Insider14d
Affirm's COO shares one approach the remote-first company uses to build a 'high-performance culture'
We get more productivity from our team." However, Linford said one persistent challenge is finding ways to get company culture to not only survive but thrive. In particular, the COO pointed to the ...